Approaches to therapy Amlodipine/Indapamide/Perindopril therapy of high arterial hypertension in ischemic heart disease patients with chronic kidney disease stage 1-3 after coronary stenting
DOI:
https://doi.org/10.18413/rrpharmacology.10.475Abstract
Introduction: Acute coronary syndrome, chronic forms of ischemic heart disease (IHD) and postinfarction cardiosclerosis are the main causes of morbidity and mortality in the world, including Russia. In the XXI century, there is an increase in comorbid pathology, especially in the combination of IHD with arterial hypertension, diabetes, chronic obstructive pulmonary disease and chronic kidney disease. Patients with IHD and chronic kidney disease have a higher incidence of coronary events and complications. The frequency of coronary events and complications indicates the need to improve the diagnosis and treatment of this group of patients. diagnosis and treatment of this group of patients. The aim of the study was to analyze the dynamics of vascular stiffness, pulmonary hypertension (PH), diastolic heart dysfunction and endothelial dysfunction indices in patients with different variants of ischemic heart disease combined with chronic kidney disease (CKD) stage 1-3 using complex therapy of combined hypotensive drug Amlodipine/Indapamide/Perindopril three months after coronary stenting and to compare them with the group of patients on conservative therapy only.
Materials and Methods: 85 patients with different forms of IHD, arterial hypertension (AH) on the background of CKD 1-3 stages, as well as data of 42 patients with IHD, AH without renal pathology were analyzed. The first group – IHD, postinfarction cardiosclerosis, CKD stage 1-3 (33 patients); the second group – acute coronary syndrome with ST-segment elevation, Myocardial infarction (MI) (30 patients); the third group – ACS without ST-segment elevation, Unstable angina (UA) (22 patients).
Results: The highest indices of vascular stiffness (Pulse wave velocity (PWV), Augmentation index (AI), CAVI, Central Systolic Blood Pressure (SBPao), central arterial pulse pressure (PP)) were registered in combination of ACS with ST-segment elevation and CKD 1-3 stages. These indices are markers of IHD progression in these patients; they also have increased pulmonary hypertension and diastolic dysfunction of the heart, endothelial dysfunction with vasodilation insufficiency in 88% of cases, which even without hemodynamically significant coronary artery stenoses according to coronary CT angiography data leads to the development of ACS with ST-segment elevation and ACS without ST-segment elevation with MI. Amlodipine/Indapamide/Perindopril was prescribed to all patients due to high arterial hypertension on admission against the background of basic therapy of IHD and coronary stenting. Coronary CT angiography in patients with comorbid renal pathology does not lead to aggravation of chronic kidney disease after 3 months, on the contrary; in this group of patients the most pronounced decrease of arterial stiffness (AS), AI, SBPao, PP with elevation of glomerular filtration rate (GFR) and decrease of creatinine in blood occurs in comparison with the group of patients who did not undergo coronary stenting, they were only on conservative therapy.
Conclusion: Prescription of three component drug Amlodipine/Indapamide/Perindopril on the background of baseline therapy especially in combination with surgical vascularization of the heart is justified.
Graphical Abstract
Keywords:
coronary heart disease, chronic kidney disease, postinfarction cardiosclerosis, unstable angina pectoris, acute coronary syndrome, coronary stenting, amlodipine, indapamide, perindoprilReferences
Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W (2021) Chlorthalidone for hypertension in advanced chronic kidney disease. New England Journal of Medicine 385(27): 2507–2519. https://doi.org/10.1056/NEJMoa2110730 [PubMed] [PMC]
Al Ghorani H, Kulenthiran S, Lauder L, Recktenwald MJM, Dederer J, Kunz M, Götzinger F, Ewen S, Ukena C, Böhm M, Mahfoud F (2024) Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes. Clinical Research in Cardiology 2024: 1–9. https://doi.org/10.1007/s00392-024-02417-2[PubMed]
Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP (2022) Acute coronary syndromes. The Lancet 399(10332): 1347–1358. https://doi.org/10.1016/s0140-6736(21)02391-6 [PubMed] [PMC]
Bhatt DL, Lopes RD, Harrington RA (2022) Diagnosis and treatment of acute coronary syndromes: a review. Journal of the American Medical Association 327(7): 662–675. https://doi.org/10.1001/jama.2022.0358 [PubMed]
Bontsevich RA, Balamutova TI, Chukhareva NA, Tsygankova OV, Batisheva GA, Paleskava A, Kompaniets OG, Ketova GG, Barysheva VO, Nevzorova VA, Martynenko IM, Pakhomov SP (2022) Physicians’ knowledge and preferences in tactics of management and rational pharmacotherapy of arterial hypertension in pregnant women (PHYGEST study).Research Results in Pharmacology 8(4): 57–64. https://doi.org/10.3897/rrpharmacology.8.80759
Bontsevich RA, Vovk YR, Gavrilova AA, Kirichenko AA, Krotkova IF, Kosmacheva ED, Kompaniets OG, Prozorova GG, Nevzorova VA, Martynenko IM, Ketova GG, Barysheva VO, Maksimov ML, Osipova OA (2021) Drug therapy of arterial hypertension: assessment of the physicians’ basic knowledge. Final results of the PHYSTARH project. Systemic Hypertension 18(2): 80–87. https://doi.org/10.26442/2075082X.2021.2.200884
Brouwers S, Sudano I, Kokubo Y, Sulaica EM (2021) Arterial hypertension. The Lancet 398(10296): 249–261. https://doi.org/10.1016/s0140-6736(21)00221-x [PubMed]
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. (2023) ESC Scientific Document Group (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal 44(38): 3720–3826. https://doi.org/10.1093/eurheartj/ehad191 [PubMed]
Chaulin AM, Grigorieva YV, Dupliakov DV (2020) Current views on the pathophysiology of atherosclerosis. Part 1. The role of lipid metabolism disorders and endothelial dysfunction (literature review). Medicine in Kuzbass [Medicina v Kuzbasse] 19(2): 34–41. https://doi.org/10.24411/2687-0053-2020-10015 [in Russian]
Ebzeyeva EY, Ostroumova OD, Doldo NM (2023) Antihypertensive therapy in comorbid patients with chronic kidney disease: a clinical observation. Russian Medical Journal. Medical Review [Meditsinskoe Obozrenie] 7(7): 418–423. https://doi.org/10.32364/2587-6821-2023-7-7-3 [in Russian]
Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N, Utami SB, Kuwabara M, Bahrudin U, Ninomiya H (2021) Uric acid as a risk factor for chronic kidney disease and cardiovascular disease – Japanese guideline on the management of asymptomatic hyperuricemia. Circulation Journal 85(2): 130–138. https://doi.org/10.1253/circj.cj-20-0406 [PubMed]
Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Park DH, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H (2022) Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. European Respiratory Journal 59(6): 2102024. https://doi.org/10.1183/13993003.02024-2021 [PubMed] [PMC]
Jankowski J, Floege J, Fliser D, Böhm M, Marx N (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143(11): 1157–1172. https://doi.org/10.1161/circulationaha.120.050686 [PubMed] [PMC]
Karpov YA, Gorbunov VM, Logunova NA (2020) Use of triple fixed combination in the treatment of arterial hypertension-capability of effective blood pressure control when using combined antihypertensive therapy: Main results of the Russian TRICOLOR observational study. Russian Journal of Cardiology [Rossiiskii Kardiologhicheskii Zhurnal] 25(10): 104–115. https://doi.org/10.15829/1560-4071-2020-4130 [in Russian]
Kobalava JD, Conradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boitsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Gleser MG, Grineva EN, Grinstein YI, Drapkina OM, Zhernakov YV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YV, Libis RA, Lopatin YM, Nebiyeridze DV, Nedoshivin AO, Ostroumova OD, Oshchepkova EV, Ratova LG, Skibitsky VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Janishevsky SN (2020) Arterial hypertension in adults. Clinical recommendations 2020. Russian Journal of Cardiology [Rossiiskii Kardiologhicheskii Zhurnal] 25(3): 149–218. https://doi.org/10.15829/1560-4071-2020-3-3786 [in Russian]
Linde JJ, Kelbæk H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, Heitmann M, Nielsen OW, Høfsten D, Kühl JT, Raymond IE, Kristiansen OP, Svendsen IH, Vall-Lamora MHD, Kragelund C, de Knegt M, Hove JD, Jørgensen T, Fornitz GG, Steffensen R, Jurlander B, Abdulla J, Lyngbæk S, Elming H, Therkelsen SK, Jørgensen E, Kløvgaard L, Bang LE, Hansen PR, Helqvist S, Galatius S, Pedersen F, Abildgaard U, Clemmensen P, Saunamäki K, Holmvang L, Engstrøm T, Gislason G, Køber LV, Kofoed KF (2020) Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. Journal of the American College of Cardiology 75(5): 453–463. https://doi.org/10.1016/j.jacc.2019.12.012
Nadirova YI, Zhabbarov OO, Bobosharipov FG, Umarova ZF, Saidaliev RS, Kodirova ShA, Mirzaeva GP, Rakhmatov AM, Zhumanazarov SB (2023) Optimisation of combined therapy in arterial hypertension with calcium channel blocker and APF inhibitor. Solution of Social Problems in Management and Economy 2(2): 181–186. https://doi.org/10.5281/zenodo.7676492
Ott C, Schmieder RE (2022) Diagnosis and treatment of arterial hypertension 2021. Kidney International 101(1): 36–46. https://doi.org/10.1016/j.kint.2021.09.026 [PubMed]
Pribylov SA, Yakovleva MV, Pribylov VS, Barbashina TA, Leonidova KO, Pribylova NN (2022) Arterial stiffness in patients with acute coronary syndrome without persistent ST-segment elevation in combination with chronic kidney disease and arterial hypertension and its correction against the background of antihypertensive therapy. Man and His Health [Chelovek i Ego Zdorov’e] (1): 19–27. https://doi.org/10.21626/vestnik/2022-1/03 [in Russian]
Safronenko AV, Lepyavka SV, Demidov IA, Nazheva MI, Maklyakov YS (2021) Optimization of premedication of patients with arterial hypertension and severe ventricular rhythm disturbances with Amiodarone-associated thyrotoxicosis.Research Results in Pharmacology 7(4): 55–62. https://doi.org/10.3897/rrpharmacology.7.78137
Tsygankova OV, Batluk TI, Latyntseva LD (2020) Improving the effectiveness of treatment of arterial hypertension and dyslipidaemia using triple fixed combination and the concept of ”vascular age”. Russian Journal of Cardiology [Rossiiskii Kardiologicheskii Zhurnal] 25(9): 66–75. https://doi.org/10.15829/1560-4071-2020-4026 [in Russian]
Waterbury TM, Tarantini G, Vogel B, Mehran R, Gersh BJ, Gulati R (2020) Non-atherosclerotic causes of acute coronary syndromes. Nature Reviews Cardiology 17(4): 229–241. https://doi.org/10.1038/s41569-019-0273-3 [PubMed]
Zhuravleva MV, Luchinina EV, Shelekhova TV, Serebrova SY, Belkov SA, Dmitriev AI, Gorodetskaya GI (2020) Combination therapy of arterial hypertension. A clinical pharmacologist’s view. Rational Pharmacotherapy in Cardiology [Ratsional’naya Farmakoterapiya v Kardiologii] 16(4): 601–606. https://doi.org/10.20996/1819-6446-2020-08-12
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sergey A. Pribylov, Kristina O. Leonidova, Vladislav S. Pribylov, Evgenia V. Gavrilyuk, Nadezhda N. Pribylova
This work is licensed under a Creative Commons Attribution 4.0 International License.